The medication is commonly used across domains where additional symptomatic support is needed for inflammatory nasal conditions. It generally contributes to easing the overall symptom load and supports patients during episodes of heightened discomfort.

Nassomet is relevant for managing symptoms associated with seasonal allergic rhinitis, perennial allergic rhinitis, and nasal polyps.

The medication is used for managing symptom clusters that may become intense or disruptive, such as frequent sneezing, nasal itching, excessive watery discharge, and nasal congestion. The primary benefit may assist in improving comfort and helps patients cope more steadily with symptom fluctuations.

In clinical settings, it is applied across conditions involving episodic or fluctuating manifestations, often used when symptoms intensify and supportive relief is needed. It assists with maintaining functional stability and supports general well-being during symptomatic phases.

Quick Fact: Supportive Management of Congestion The medication is considered relevant for easing symptoms that interfere with daily functioning, applied in scenarios where additional management of discomfort is required for nasal congestion.

Nassomet (mometasone furoate nasal spray) is subject to strict regulatory eligibility rules that define who may or may not use the medicine.

Contraindications (Must Not Use):

• Hypersensitivity: The medicine is contraindicated in patients with known allergy to mometasone furoate or any of its ingredients.
• Nasal Injury/Infection: Use must be avoided until healing has occurred in patients with recent nasal surgery, nasal trauma, or unhealed ulcers in the nose. It is also not recommended for use in patients with untreated local infections of the nasal mucosa.

Age-Related Eligibility:

Indication	Minimum Approved Age	Use Classification
Allergic Rhinitis	ge 2 or 3 years*	Established
Nasal Polyps	ge 18 years	Established

*Use is generally not established as safe or effective in children younger than the minimum approved age for each indication.

Special Populations and Conditions:

• Pregnancy/Lactation: Should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, with newborns observed for hypoadrenalism. It is unknown if the drug is excreted in human milk, requiring caution and a decision to discontinue the drug or breastfeeding.
• Systemic Conditions: Caution is required in patients with certain systemic infections (e.g., active or quiescent tuberculosis) and in those with a history of glaucoma or cataracts.

Interactions with other medicines and products

The primary concern regarding drug interactions with Nassomet (mometasone furoate) is the potential for increased systemic exposure when co-administered with certain medicines.

Pharmacokinetic Mechanism and Interacting Agents

Mometasone furoate is primarily metabolized by the cytochrome P450 3A4 (CYP3A4) enzyme system in the liver. Products that act as strong CYP3A4 inhibitors are expected to increase the drug's concentration in the bloodstream, raising the risk of systemic corticosteroid side effects.

Interacting medicinal products and classes:

• Strong CYP3A4 Inhibitors: Co-treatment with these agents, which include certain antiretrovirals (e.g., cobicistat-containing products) and some antifungal medications, should be approached with caution or avoided. Regulatory guidance recommends that this combination should only be used if the benefit outweighs the increased risk, and the patient must be carefully monitored for signs of systemic corticosteroid effects.
• Loratadine: A clinical interaction study conducted with the antihistamine loratadine showed that no drug interactions were observed. Therefore, co-administration is generally considered acceptable.

Other Interaction Contexts

Particular care should be taken when patients are being transferred from long-term systemic corticosteroid therapy to Nassomet nasal spray, as they may remain at risk for adrenal suppression, which is a key systemic effect of corticosteroids.

Nassomet, which is mometasone furoate, is a synthetic glucocorticoid agonist. Following intranasal administration, the compound accumulates in the nasal mucosa where it diffuses across cell membranes and binds with high affinity to the intracellular glucocorticoid receptor ( GR/NR3C1).

Binding induces a conformational change, leading to receptor translocation into the nucleus. The agonist-receptor complex modulates gene transcription primarily through two mechanisms: transactivation and transrepression. In the transactivation pathway, the complex dimerizes and binds to Glucocorticoid Response Elements (GREs) on target genes, increasing the expression of anti-inflammatory proteins, such as lipocortins. In transrepression, the complex inhibits the activity of pro-inflammatory transcription factors, including NF-kB (Nuclear Factor kappa-light-chain-enhancer of activated B cells) and AP-1 (Activator Protein-1). This cellular cascade results in decreased synthesis of pro-inflammatory mediators, including cytokines ( IL-4, IL-5), chemokines ( RANTES), eicosanoids, and adhesion molecules ( ICAM-1, VCAM-1). The molecular consequences include the induction of apoptosis in T-lymphocytes and eosinophils, reduced recruitment of these and other inflammatory cells to the nasal tissue, and diminished vascular permeability. The system-level physiological consequence is the localized modulation of inflammatory processes within the nasal passages.

Nassomet is a prescription mometasone furoate nasal spray indicated for intranasal use only, primarily for the treatment and prophylaxis of allergic rhinitis symptoms and the treatment of nasal polyps in adults.

Preparation and Priming

1. Shake the bottle gently before each use.
2. Prime the pump before initial use by actuating (pumping) the spray 10 times, or until a fine mist is produced. If the product is unused for more than one week, it must be re-primed by actuating twice, or until a fine mist appears.
3. Gently blow your nose to clear your nostrils before administration.

Administration Steps

1. Hold the bottle with your forefinger and middle finger on the shoulder of the applicator and your thumb supporting the bottom.
2. Close one nostril by pressing a finger against the side of your nose.
3. Tilt your head slightly forward and gently insert the nasal applicator tip into the open nostril, aiming the spray tip toward the side of the nostril, away from the center of your nose (nasal septum).
4. While slowly inhaling through the nose, firmly press down on the applicator to release the spray.
5. Breathe out through your mouth.
6. Repeat the process in the same nostril for a second spray if instructed by a healthcare provider, and then repeat the full process in the other nostril.
7. After use, wipe the applicator tip with a clean tissue and replace the cap.

Dosage and Duration

The recommended dosage is based on the condition being treated, but typical adult dosing for allergic rhinitis is two sprays in each nostril once daily. Full therapeutic benefit may not be achieved for up to two weeks, and regular, consistent use is essential for symptom control. Do not exceed the prescribed dose. If a dose is missed, administer it as soon as you remember, unless it is almost time for the next scheduled dose, in which case the missed dose should be skipped; do not use extra sprays to make up for a missed dose.

Research Evidence / Overview of Studies

Efficacy in Allergic Rhinitis

Research has explored whether this combination may improve symptoms in participants with moderate-to-severe allergic rhinitis.

The combination uses two active components: an antihistamine (Loratadine) and a decongestant (Pseudoephedrine). Studies have assessed the clinical questions surrounding this dual-action approach.

Phase III Clinical Trials

A key randomized, controlled trial examined the combination's impact on perennial allergic rhinitis. Findings included:

• The study examined whether the combination could result in a reduction of nasal congestion and rhinorrhea over time in adults.
• Research has investigated the effects of the combined formulation on pain and discomfort associated with seasonal allergies.
• The combination was studied for its potential to impact quality of life scores, as part of the evaluation.
• Research has compared the combination with single-agent antihistamines, noting the different outcomes when addressing nasal blockage.

Dosage and Administration Studied

In the studied protocol, participants typically took one tablet twice daily for two weeks. The research evaluated the changes in patient-reported symptom scores during this period.

---

Safety and Tolerability

The tolerability of the combination was a focus of the research.

Studies evaluated the tolerability of the combination in participants, including those with controlled hypertension. Common effects documented in the trials included dry mouth and mild insomnia or nervousness, which are often associated with the decongestant component.

Potential Interactions Studied

Studies of the drug’s interactions included alcohol, as well as specific medications that affect the liver's metabolic pathways (such as certain potent CYP3A4 inhibitors). The research documented the change in drug levels when these substances were co-administered.

Key Studies & References

1. Comparative efficacy and safety of a once-daily loratadine-pseudoephedrine combination versus its components alone and placebo in the management of seasonal allergic rhinitis

Common questions about Nassomet (FAQ)

---

Q: What should I do if I miss a dose of the nasal spray?

Regulatory information indicates that the missed dose may be administered as soon as you remember. However, if it is almost time for your next scheduled dose, official information states that you should skip the missed dose and continue with your regular schedule. The labeling advises against using extra sprays to compensate for a missed dose.

---

Q: What should I do if the spray pump is not working when I first try to use it?

Prior to initial use, the product must be primed by pumping the spray 10 times until a fine mist is clearly produced. If a fine mist is not produced after priming, regulatory information advises consulting the full Instructions for Use, which include steps for cleaning the actuator. If you have been using the spray, it must be re-primed if it hasn't been used for more than one week.

---

Q: For how long can I safely use Nassomet continuously?

Regulatory documents state that if the nasal spray is used over several months or longer, the need for periodic examination by a healthcare provider is documented. This check-up is intended to monitor for any localized changes in the nasal passages, such as nasal ulceration or perforation.

---

Q: Are there any specific storage precautions I need to follow for Nassomet?

Nassomet must be stored at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F), and must not be frozen. Official documents state that the product should be kept tightly closed in the original container, and protected from light and moisture.

---

Q: What happens inside the nose when Nassomet is sprayed?

Nassomet is classified as a corticosteroid, which acts as an anti-inflammatory medicine. When sprayed into the nose, it works locally to reduce the swelling, irritation, and excess mucus production associated with inflammation and allergies. It achieves this by affecting the production of inflammatory chemicals, such as cytokines, directly within the nasal lining.

---

Q: Is Nassomet safe for use in children?

According to the official product labeling, this medicine is indicated for treating allergic rhinitis symptoms in children who are 2 years of age and older. The medicine is not recommended for use in children younger than 2 years of age for this indication.

---

Q: What should I do if I accidentally swallow some of the spray?

Nassomet is intended for intranasal use only. Although a small amount is inevitably swallowed and absorbed, this medicine is formulated for localized action. Concerns regarding swallowing a large amount should be discussed with a healthcare provider.

---

Q: Can I use Nassomet if I am trying to get pregnant?

Official labeling advises that the medicine should be used during pregnancy only if the potential benefit justifies any potential risk to the fetus. Decisions regarding use by women who are planning to become pregnant or are currently pregnant should be made in consultation with a healthcare provider.

How to Store and Dispose of Nassomet? (Mometasone Furoate Nasal Spray)

Nassomet must be stored strictly according to regulatory guidelines to maintain its stability.

---

️ Storage Requirements

Detail	Requirement
Temperature	Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Do not freeze.
Protection	Keep in the original container, tightly closed, and protect from light and moisture.
Child Safety	Keep out of the sight and reach of children.

---

️ Stability and Disposal

Nassomet must be discarded 75 days after the first use (or 2 months, depending on the regulatory label). Unused or expired medicine must not be thrown away via wastewater or household waste. Consult a pharmacist for proper disposal methods to protect the environment.